MedTrace Logo

Spectroscopic Magnetic Resonance Imaging of Glioma

NCT03677999 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2025-02-17

No results posted yet for this study

Summary

The study is designed to develop and test new Magnetic Resonance Imaging methods that can improve the characterization of brain cancer and facilitate improved clinical care of these participants.

Conditions

  • Brain Tumor-Glioma

Interventions

DIAGNOSTIC_TEST

MEGA-PRESS sequence Magnetic Resonance Spectroscopy

MRS protocols and novel MRI methods that allow detection and quantification of 2 hydroxyglutarates (2HG) as well as the physiologic consequences of 2HG accumulation.

Sponsors & Collaborators

Principal Investigators

  • Clark Chen, MD, PhD · University of Minnesota

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-01
Primary Completion
2024-09-14
Completion
2025-09-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03677999 on ClinicalTrials.gov